Article
Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer
2021-11-24
Abstract excerpt
<h4>Background: </h4> Although the Decipher genomic classifier has been validated as a prognostic tool for several prostate cancer endpoints, little is known about its role in assessing risks of biopsy reclassification among patients on active surveillance, a key event that often triggers treatment. <h4>Objective:</h4> To evaluate the association between Decipher genomic classifier and biopsy Gleason upgrade among...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 5575a2c0-3128-5ba7-97cc-0a1ea99ee041
- DOI
- 10.1101/2021.11.22.21266727
